Drugs in ATC Class H05AA

Up to Top Level ATC Classes

Up to H - Systemic hormonal preparations, excluding sex hormones and insulins

Up to H05 - CALCIUM HOMEOSTASIS

Up to H05A - PARATHYROID HORMONES AND ANALOGUES

Drugs in ATC Class: H05AA - Parathyroid hormones and analogues

Tradename	Generic Name
BONSITY	teriparatide
FORTEO	teriparatide
PARATHAR	teriparatide acetate
TERIPARATIDE	teriparatide
TYMLOS	abaloparatide

H05AA Market Analysis and Financial Projection

The market for parathyroid hormone (PTH) analogs classified under ATC code H05AA is experiencing robust growth, driven by increasing demand for osteoporosis and hypoparathyroidism treatments. Here’s a breakdown of key dynamics and patent trends:

Market Dynamics

• Growth Projections:

  • Valued at USD 1.5 billion in 2022, the market is projected to reach USD 2.9–4.1 billion by 2030–2033, growing at a CAGR of 7.5%–8.9%[3][11][14].
  • Drivers include aging populations (over 54 million Americans affected by osteoporosis[3][14]), rising healthcare expenditures (global spending reached $8.3 trillion in 2022[3]), and advancements in drug delivery systems like nasal sprays[4].

• Key Players:
  Major pharmaceutical companies dominate, including Pfizer, Eli Lilly, and Abbott Laboratories, with teriparatide (Forteo®) and abaloparatide as leading products[3][8][14]. Emerging markets in Asia-Pacific and Latin America are growth hotspots due to improving healthcare infrastructure[3][11].

• Applications:
  Primarily used for osteoporosis (rebuilding bone density) and hypoparathyroidism, with expanding applications in regenerative medicine and veterinary care[3][14].

• Challenges:
  High treatment costs (e.g., teriparatide’s injectable formulation averages $14.29 per dose[6]) and regulatory hurdles in emerging markets[3][8].

---

Patent Landscape

• Innovation Focus:

  • Delivery Mechanisms: Patents like US 8,076,290 cover non-invasive formulations (e.g., nasal sprays) for PTH analogs, addressing patient compliance issues[4].
  • Molecular Variants: Patents such as US6921750B2 and US5556940 protect peptide analogs with enhanced efficacy for osteoporosis treatment[9][13][16].

• Strategic Moves:

  • Licensing Agreements: Aegis Therapeutics licensed its nasal delivery technology to Azelon Pharmaceuticals, enabling non-injectable teriparatide[4].
  • Expired vs. Active Patents: While older patents (e.g., Forteo®) face generics, newer ones (e.g., palopegteriparatide) extend market exclusivity[5][13].

• Geographic Trends:

  • North America and Europe lead in patent filings, reflecting strong R&D investment[3][15].
  • Increasing filings in Asia-Pacific signal rising regional competition[8][14].

---

Competitive Strategies

• R&D Investment: Companies prioritize biologics and combination therapies (e.g., PTH analogs with bisphosphonates)[9][16].
• Market Expansion: Partnerships to penetrate emerging markets and diversify applications (e.g., veterinary use)[3][14].

Key Takeaways

• The H05AA market is poised for sustained growth, fueled by demographic trends and innovation in drug delivery.
• Patent strategies focus on circumventing generics through novel formulations and expanding therapeutic applications.
• Emerging markets and non-invasive therapies represent untapped opportunities for stakeholders.

“Non-injectable PTH formulations could revolutionize osteoporosis treatment by improving adherence.” – [Aegis Therapeutics, 2011][4].

For businesses, leveraging patent analytics to track competitor activity and regional trends will be critical for maintaining market leadership[15].

---

FAQs

1. What conditions do H05AA drugs treat?
   Primarily osteoporosis and hypoparathyroidism by regulating calcium levels[2][3].
2. Which companies lead the PTH analog market?
   Pfizer, Eli Lilly, and Abbott Laboratories dominate with products like Forteo®[3][8].
3. How do patents influence market dynamics?
   They protect novel formulations (e.g., nasal sprays) and extend revenue streams beyond generics[4][9].
4. What growth opportunities exist in emerging markets?
   Rising healthcare spending and untreated patient populations in Asia-Pacific[3][11].
5. Are non-injectable PTH analogs available?
   Yes, nasal sprays and oral formulations are in development to replace daily injections[4].

References

1. https://atcddd.fhi.no/atc_ddd_index/?code=H05AA&showdescription=yes
2. https://go.drugbank.com/drugs/DB18676
3. https://www.verifiedmarketreports.com/product/parathyroid-hormone-analog-market/
4. https://www.biospace.com/aegis-therapeutics-llc-awarded-patent-for-parathyroid-hormone-pth-peptide-drug-formulations-suitable-for-metered-nasal-spray-and-oral-delivery
5. https://atcddd.fhi.no/atc_ddd_index/?code=H05AA&showdescription=no
6. https://pdfs.semanticscholar.org/e50f/a50e41da0b5c8443c69b439480c1a742f158.pdf
7. https://www.zva.gov.lv/sites/default/files/2017-12/Baltic%20Statistics%20on%20Medicines%202013%20-%202015.pdf
8. https://www.cognitivemarketresearch.com/parathyroid-hormone-analog-market-report
9. https://patents.justia.com/patent/5556940
10. https://www.atccode.com/H05AA
11. https://github.com/meghajagadale2711/InsightSphere/blob/main/Parathyroid-Hormone-Analog-Market-Size-and-Opportunity-Analysis.md
12. https://pure.hud.ac.uk/files/67009246/28_Final_thesis.pdf
13. https://patents.google.com/patent/US6921750B2/en
14. https://github.com/vandelmanize/Market-Research-Report-List-1/blob/main/parathyroid-hormone-analog-market.md
15. https://sagaciousresearch.com/blog/what-is-a-patent-landscape-report-how-to-create-it/
16. https://pubchem.ncbi.nlm.nih.gov/patent/US-RE40850-E